Sio Gene Therapies Inc
F:6YY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clearwater Paper Corp
NYSE:CLW
|
US |
|
C
|
Componenta Oyj
OMXH:CTH1V
|
FI |
Sio Gene Therapies Inc
Cash from Operating Activities
Sio Gene Therapies Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sio Gene Therapies Inc
F:6YY
|
Cash from Operating Activities
-$36.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$19B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$10B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
Sio Gene Therapies Inc
Glance View
Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2015-06-11. The firm is focused on developing gene therapies for neurodegenerative diseases. The firm is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The firm is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.
See Also
What is Sio Gene Therapies Inc's Cash from Operating Activities?
Cash from Operating Activities
-36.5m
USD
Based on the financial report for Dec 31, 2022, Sio Gene Therapies Inc's Cash from Operating Activities amounts to -36.5m USD.
What is Sio Gene Therapies Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
29%
Over the last year, the Cash from Operating Activities growth was 31%. The average annual Cash from Operating Activities growth rates for Sio Gene Therapies Inc have been 16% over the past three years , 29% over the past five years .
